Clinical Trial Update: The Efficacy and Safety of Ensartinib As Adjuvant Therapy in Stage I ALK-positive NSCLC Patients with High Risk Factors [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating ensartinib as adjuvant therapy for stage I ALK-positive non-small cell lung cancer with high-risk factors; the study is curr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Ensartinib (Ensartinib)

Snippet

Sponsor: Shanghai Pulmonary Hospital, Shanghai, China | Conditions: NSCLC, ALK | Phase 2 | Status: NOT_YET_RECRUITING